pharmaphorum16m
GSK hails survival data with revived myeloma drug Blenrep
GSK's drive to resurrect its multiple myeloma therapy Blenrep has continued with new data from the DREAMM-7 trial showing an ...
The Pharma Letter21h
GSK inks multi-target alliance with Versalius
Cambridge, USA-based Vesalius Therapeutics has entered into a multi-target strategic alliance with the UK’s GSK to discover ...
BioPharma Dive1d
GSK partners with Flagship startup to hunt for Parkinson’s drugs
Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...
Taylor Swift: The Brand Unveiled - Groundbreaking 12-Year Study Exposes the True Power of Her Music's Commercial Appeal
Consumers Rank Nearly 200 Taylor Swift Tracks, Revealing the Commercial Truth Behind Her Last 10 Albums and the True Value of ...
manilatimes1d
Zenas BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
Concluded targeted enrollment of Phase 3 INDIGO trial evaluating obexelimab for the treatment of Immunoglobulin G4-Related ...
GSK Vaccines’ shingles ad campaign warns about the year-round threat
The print ads featured a prominent display of a person’s back, highlighting where shingles rashes typically emerge.
FierceBiotech2d
GSK inks Parkinson's pact with Flagship's Vesalius for $570M-plus biobucks
GSK is paying $80 million to ink a multi-target neurodegenerative pact with Flagship-founded Vesalius Therapeutics that ...
Workday's UK profits soar as it doubles down on investment and partnerships
The US group's division has reported a pre-tax profit of $39.5m (£30.6m) for the 12 months to 31 January, 2024, according to ...
The Pharma Letter3d
GSK still yielding more than 4%, notes Morningstar
In its third quarter results of 2024, pharmaceutical giant GSK confirmed it would pay a quarterly dividend of 15 pence. However, Morningstar analyst Christopher Johnson says he believes that GSK’s ...